Antisense Therapeutics =Market cap $15 Million / Phase 2 Results of DMD Trial expected next Quarter / Former Chairman of Sarepta and inventors of Eteplirsen on board of this small company = Could be the next Potential 5000% Gem like Sarepta (SRPT) , Its also a super attractive takeover candidate .The hottest Pick in the pharma sector .GL Antisense Therapeutics (ANP.AX) or (OTC: ATHJF) but real volume to date only on ASX /Australia
Market Cap $15 Million
Cash $3 Million ( enough untill mid to late 2020)
"Former SRPT Chairman, William (Bill) Goolsbee, is a director on ANP’s Board. Goolsbee is also the Chairman of the company’s scientific advisory board which includes the two Australian scientists (Profs Steve Wilton and Sue Fletcher) who are the inventors of Sarepta’s drug, eteplirsen. Bill has extensive experience and networks in the field of DMD drug development and commercialisation which he is imparting on ANP in their development of ATL1102." Company Presentation https://www.asx.com.au/asxpdf/20190625/pdf/44630r6yht8gkg.pdf ASX Junior’s Flagship Immunomodulatory Drug Could Turn the Tide in Duchenne Muscular Dystrophy Treatment https://www.nextbiotech.com.au/asx-juniors-flagship-immunomodulatory-drug-could-turn-the-tide-in-duchenne-muscular-dystrophy-treatment/ Could Antisense be the next multi-billion Duchenne Muscular Dystrophy biotech? https://stockhead.com.au/health/could-antisense-be-the-next-multi-billion-duchenne-muscular-dystrophy-biotech/
“I joined the board of Sarepta in 2007. We were in a very similar circumstance as Antisense,” he told Stockhead.
“We had a low market cap, we had low cash balance, we were fighting to get to the point where we could prove out our drug. Now look at what’s changed in the last 10 years. That’s what we’re trying to achieve at Antisense.” ANTISENSE THERAPEUTICS SUMMARY & VALUE DRIVERS
ANP: Why partnering with big biotech has its benefits..
Advanced stage product pipeline –two compounds with positive Phase II clinical results published in high quality peer reviewed scientific journalsHighly regarded substantial shareholders –have increased their holdingsPhase II clinical trial in Duchenne Muscular Dystrophy (DMD)
– ATL1102−Trial is fully enrolled, results expected Q4 CY2019
−Phase IIb trial design and approval process to run in parallel, accelerating development of ATL1102
−Drug potentially complementary to other DMD programs e.g. SareptaTherapeutics
−Significantly ‘underserved market’ with comparable company benchmarks demonstrating substantial value creation potential
Establishing Early Access Program (EAP) for acromegaly
– ATL1103−Plan to provide ATL1103 to acromegaly patients under an EAP in Europe
−Potential for income generation & partnering to further develop the compound https://youtu.be/aiAZIker8Eg